Statement of Ownership (sc 13g)
13 11월 2019 - 11:45PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
Armata
Pharmaceuticals, Inc.
(Name
of Issuer)
Common
Stock, par value $0.01 per share
(Title
of Class of Securities)
04216R
102
(CUSIP
Number)
October
22, 2019
(Date
of Event Which Requires Filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
|
[ ]
|
Rule
13d-1(b)
|
|
[X]
|
Rule
13d-1(c)
|
|
[ ]
|
Rule
13d-1(d)
|
*The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided
in a prior cover page.
The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
Persons
who respond to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB control number.
Schedule
13G
CUSIP
No. 04216R 102
|
Page
2 of 5
|
1. Names of Reporting Persons.
Synthetic Genomics,
Inc.
|
2. Check the Appropriate Box if a Member of a Group
(a) [ ]
(b) [ ]
|
3. SEC Use Only
|
4. Citizenship or Place of Organization
Delaware
|
Number of Shares
Beneficially
Owned by
Each Reporting
Person With:
|
5. Sole Voting Power
516,976 (see Item 4 below)
|
6. Shared Voting Power
0
|
7. Sole Dispositive Power
516,976 (see Item 4 below).
|
8. Shared Dispositive Power
0
|
9. Aggregate Amount Beneficially Owned by Each Reporting Person
516,976 (see Item 4 below)
|
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
[ ]
|
11. Percent of Class Represented by Amount in Row (9)
5.2%
|
12. Type of Reporting Person
CO
|
Schedule
13G
CUSIP
No. 04216R 102
|
Page
3 of 5
|
Item
1.
(a)
Name of Issuer: Armata Pharmaceuticals, Inc.
(b)
Address of Issuer’s Principal Executive Offices:
4503
Glencoe Avenue
Marina del Rey, California 90292
Item
2.
(a)
Name of Person Filing: Synthetic Genomics, Inc. (the “Reporting Person”)
(b)
Address of Principal Business Office, or if None, Residence:
11149
North Torrey Pines Road
La
Jolla, California 92037
(c)
Citizenship: Synthetic Genomics, Inc. is a corporation incorporated in the State of Delaware.
(d)
Title of Class of Securities: Common Stock, par value $0.01 per share
(e)
CUSIP Number: 04216R 102
Item
3. If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:
Not
Applicable
Item
4. Ownership.
Provide
the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in
Item 1.
(a)
Amount beneficially owned: 516,976 shares
(b)
Percent of class: 5.2%
(c)
Number of shares as to which such person has:
(i)
Sole power to vote or to direct the vote: 516,976 shares
(ii)
Shared power to vote or to direct the vote: None
(iii)
Sole power to dispose or to direct the disposition of: 516,976 shares
(iv)
Shared power to dispose or to direct the disposition of: None.
The
percentages used herein are calculated based on 9,934,299 shares of Common Stock reported by the Issuer to be issued and outstanding
as of September 30, 2019, as disclosed in the Issuer’s Proxy Statement on Schedule 14A filed with the Securities and Exchange
Commission on October 22, 2019.
Item
5. Ownership of Five Percent or Less of a Class.
Not
applicable.
Item
6. Ownership of More than Five Percent on Behalf of Another Person.
Not
Applicable.
Schedule
13G
CUSIP
No. 04216R 102
|
Page
4 of 5
|
Item
7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
or Control Person.
Not
Applicable.
Item 8. Identification and Classification of Members of the Group.
Not
Applicable.
Item
9. Notice of Dissolution of a Group.
Not
Applicable.
Item
10. Certification.
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than
activities solely in connection with a nomination under § 240.14a-11.
Schedule
13G
CUSIP
No. 04216R 102
|
Page
5 of 5
|
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
|
Synthetic Genomics, Inc.
|
|
|
|
November
12, 2019
|
By:
|
/s/
Robert Cutler
|
(Date)
|
Name:
|
Robert
Cutler
|
|
Title:
|
General
Counsel
|
Ampliphi Biosciences Corp. (AMEX:APHB)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Ampliphi Biosciences Corp. (AMEX:APHB)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024